Markedly improvement of glycaemic control in diabetic patients with chronic hepatitis C achieving sustained virologic response after direct acting antiviral therapy: results of a prospective controlled study

Ciancio, Alessia; Bosio, Raul M.; Bó, Suzane Dal; Pellegrini, M.; Sacco, Marco; Vogliotti, Edoardo; Fassio, Giulia; Degerfeld, A. Bianco Mauthe; Gallo, Martina; Giordanino, Chiara; Bergamo, Lodovico Terzi di; Smedile, A.; Rizzetto, Mario; Saracco, G.M.

doi:10.1016/s0168-8278(17)30879-6

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical benefits of DAAs in cirrhotic and advanced liver disease LT patients have been described. However, despite the substantial and growing evidence on the use of DAAs in the posttransplant setting, questions remain (Table ) …”

Section: Authors’ Viewpointmentioning

confidence: 99%

The road map toward an hepatitis C virus-free transplant population

Berenguer

Agarwal

Burra

et al. 2018

American Journal of Transplantation

View full text Add to dashboard Cite

Antiviral therapy to eradicate hepatitis C virus (HCV) infection improves outcomes in patients undergoing liver transplantation (LT) for advanced chronic HCV with or without hepatocellular carcinoma. Traditionally, antiviral therapy focused on the use of interferon (IFN)-based regimens, with antiviral treatment initiated in the posttransplant period once recurrent HCV disease with fibrosis in the allograft was identified. The use of IFN-based therapy was limited in pretransplant patients with advanced liver disease. Earlier intervention, either before transplantation or early after LT, is now feasible with the advent of second-generation direct-acting antiviral agents (DAAs) with superior tolerability and efficacy to IFN-based therapy. These agents have the potential to reduce the number of patients developing HCV-related complications requiring LT and retransplantation, as well as reducing the demand for donor organs. We discuss the pros and cons of pretransplant, peritransplant, and posttransplant therapy with current DAAs, citing available data from clinical trials and real-world experience.

show abstract

Section: Authors’ Viewpointmentioning

confidence: 99%